Floatz logo

2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-

Male Breast Cancer

National Cancer Institute (NCI)Small moleculePhase 1/2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

10 Active assets in the Male Breast Cancer cohort.

Asset / SponsorPhaseRating
Irinotecan
University of California, Irvine
Phase 2BBB
Cyclophosphamide
Wake Forest University Health Sciences
Phase 2BBB
FILGRASTIM
University of Washington
Phase 2BBB
Inno-206
National Cancer Institute (NCI)
Phase 2BBB
Cediranib
University of Chicago
Phase 2BB

View all 50 →

Same molecule, other indications

2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- is also rated in:

acute monocytic leukemiaDormant
BBB
Indicative ·
74 / 100
View asset →
acute megakaryoblastic leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
acute myeloid leukemia with minimal differentiationDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →